pentobarbital will lessen the extent or outcome of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay clear of coadministration. Solid or reasonable CYP3A inducers may perhaps reduce cobimetinib systemic exposure by >eighty% and minimize its efficacy.